Key result
Baseline plasma levels of miR-155 and miR-206 predicted biopsy-proven inflammatory cardiomyopathy (OR 2.61 and 2.65, respectively), demonstrating superior diagnostic performance compared to Lake Louise criteria.
Why the study?
Establishing a non-invasive diagnosis of inflammatory cardiomyopathy remains challenging despite advances in cardiac magnetic resonance imaging, and microRNAs may be involved in its pathogenesis.
Do plasma levels of miR-155 and miR-206 improve the diagnostic accuracy for inflammatory cardiomyopathy in patients with suspected myocarditis compared to standard criteria?
Observational (n=89)
No
Do plasma levels of miR-155 and miR-206 improve the diagnostic accuracy for inflammatory cardiomyopathy in patients with suspected myocarditis compared to standard criteria?
Odds Ratio: 2.61 (95% CI 1.28–5.31)
p-value: p=0.008
Plasma levels of miR-155 and miR-206 offer superior diagnostic performance for inflammatory cardiomyopathy compared to standard Lake Louise criteria and conventional biomarkers.
May aid noninvasive diagnosis of inflammatory cardiomyopathy; hypothesis-generating and requires validation before practice change.
AIMS: Establishing a diagnosis of inflammatory cardiomyopathy (iCMP) by non-invasive means remains challenging despite advances in cardiac magnetic resonance imaging. Previous studies suggested the involvement of microRNAs in the pathogenesis of iCMP. We examined the association of a predefined set of circulatory microRNAs with clinical characteristics of iCMP and evaluated their diagnostic performance in suspected iCMP. METHODS AND RESULTS: Eighty-nine patients with clinical suspicion of iCMP were included in the analysis. All patients underwent cardiac catheterization with left ventricular endomyocardial biopsy, echocardiography, and cardiac magnetic resonance imaging applying the Lake Louise criteria (LLC). Plasma levels of miR-21, miR-126, miR-133a, miR-146b, miR-155, and miR-206 were determined using real-time polymerase chain reaction. Based on immunohistological findings on endomyocardial biopsy, iCMP was diagnosed in 67% of study participants (n = 60). Plasma levels of miR-155 and miR-206 were significantly increased in patients with iCMP as compared with patients with dilated cardiomyopathy (P = 0.008 and P = 0.009, respectively). In receiver operating characteristic curve analysis, miR-155 and miR-206 demonstrated superior diagnostic performance for iCMP (0.68 and 0.67, respectively) compared with LLC [area under the curve (AUC) 0.60], Troponin T (AUC 0.51), and N-terminal pro-brain natriuretic peptide (AUC 0.51). While baseline miR-155 and miR-206 plasma levels were predictive for biopsy-proven iCMP (odds ratio = 2.61, 95% confidence interval = 1.28-5.31, P = 0.008 and odds ratio = 2.65, 95% confidence interval = 1.27-5.52, P = 0.009) on univariate logistic regression analysis, the presence of positive LLC, high baseline C-reactive protein, or presence of clinical symptoms and signs of viral infection failed to predict iCMP (P > 0.05, respectively). CONCLUSIONS: The present data suggest that plasma levels of miR-206 and miR-155 are potential novel biomarkers for confirming the diagnosis of iCMP.
No takes yet. Share an insight, caveat, or question.
Obradović et al. (2021) conducted an observational in Inflammatory cardiomyopathy (n=89). Plasma miR-155 and miR-206 vs. Dilated cardiomyopathy (DCM) was evaluated on Biopsy-proven inflammatory cardiomyopathy (OR 2.61, 95% CI 1.28-5.31, p=0.008). Baseline plasma levels of miR-155 and miR-206 predicted biopsy-proven inflammatory cardiomyopathy (OR 2.61 and 2.65, respectively), demonstrating superior diagnostic performance compared to Lake Louise criteria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: